CN109200023A - A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection - Google Patents
A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection Download PDFInfo
- Publication number
- CN109200023A CN109200023A CN201710554169.5A CN201710554169A CN109200023A CN 109200023 A CN109200023 A CN 109200023A CN 201710554169 A CN201710554169 A CN 201710554169A CN 109200023 A CN109200023 A CN 109200023A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- propacetamol
- injection
- hydrochloride
- stabilizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Abstract
The invention discloses a kind of pharmaceutical compositions of the hydrochloric Propacetamol of injection, including following weight percentage components: Propacetamol Hydrochloride 66-75%；PH adjusting agent 4-10%；Stabilizer 14-30%.The invention also discloses the preparation methods of aforementioned pharmaceutical compositions.Propacetamol Hydrochloride composition provided by the invention is freeze drying powder injection, and by the way that buffer and stabilizer is added, after so that the injection obtained is dissolved in solution, stability is good, highly-safe.
Description
Technical field
The present invention relates to the injections containing analgesic, and in particular to a kind of Propacetamol Hydrochloride injection of waterproof solution
Agent.
Background technique
Propacetamol Hydrochloride, chemical name 4- acetaminophenol lignocaine acetate hydrochloride, is that (Bu Maishi is expensive by USPA
It is precious) like derivatives of the paracetamol (paracetamol) of company's exploitation.The medicine can intramuscular injection or intravenously administrable, it is clinical main
For the symptomatic treatment of pain, especially post-surgical pain and cancer pain.
Phenolic ester structure in Propacetamol Hydrochloride structure containing facile hydrolysis makes its facile hydrolysis generate acetic acid, acetparaminosalol
Phenol and para-aminophenol.Paracetamol is unstable, can further be degraded to para-aminophenol and benzoquinone imine.
Bright et al. the report of Wei Li, because the hydrolysate acetic acid and para-aminophenol of Propacetamol Hydrochloride have acidity, hydrochloric acid
Propacetamol and common infusions liquid (5% glucose injection, 10% glucose injection, 0.9% sodium chloride injection, grape
Sugared sodium chloride injection, fructose injection) compatibility when, pH value of solution becomes smaller quickly, and after compatibility half an hour, 5 kinds of pH value of solution are respectively less than
4, and then influence stability when Propacetamol Hydrochloride clinical application.
When presently commercially available hydrochloride for injection Propacetamol clinical use, be with 0.9% sodium chloride injection compatibility, pass through
By Infusion Time control in 15 minutes, the unstable influence to clinical application of injection is dissolved in reduce.The present inventor's research
It was found that pH value of solution is between 3.9-4.6 when presently commercially available hydrochloride for injection Propacetamol and 5 kinds of common infusions liquid compatibilities；
After compatibility 15 minutes, pH value of solution drops between 3.7-4.0, and having exceeded human body can tolerate pH range 4.0~9.0.Because of human body
When beyond the pH range of tolerance infusion, vein or capillary spasm can be caused, local blood supply is reduced, cause tissue ischemia,
Phlebitis occurs for anoxic.PH value is lower, and phlebitis probability of happening is bigger.There can be operational delay when due to clinical application
Property, commercially available hydrochloride for injection Propacetamol has the risk for causing phlebitis, and then influences safety when clinical application.
In addition, the catabolite benzoquinone imine of Propacetamol Hydrochloride can be such that Propacetamol Hydrochloride colours, and human body can be produced
Raw toxic side effect.Presently commercially available Propacetamol Hydrochloride powder-injection is not added with any auxiliary material, as the temperature increases or contact light,
The degradation rate of Propacetamol Hydrochloride is accelerated, content is lower, and the soft, metachromatism that collapses easily occurs, further influence the third pa of hydrochloric acid he
Not quality when clinical application.
The domestic document or patent report that there is no hydrolytically unstable when in relation to overcoming hydrochloride for injection Propacetamol to apply at present
Road.Therefore, it is necessary to research and develop a kind of new hydrochloride for injection Propacetamol, by improving it because pH caused by hydrolysate drops
It is low it is fast, collapse soft, discoloration the problems such as, to improve stability, the safety issue when hydrochloride for injection Propacetamol clinical application.
Summary of the invention
The technical problem to be solved by the present invention is to overcome the deficiencies of the prior art and provide a kind of hydrochloric third pa of injection
His pharmaceutical composition not, effectively reduces the hydrolysis of hydrochloride for injection Propacetamol in aqueous solution in the right way, improves
The stability problem of its injection.
The present invention also technical problems to be solved are to provide the preparation side of the pharmaceutical composition of above-mentioned hydrochloric Propacetamol
Method.
In order to solve the above technical problems, The technical solution adopted by the invention is as follows:
A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection, including following weight percentage components:
Propacetamol Hydrochloride 66-75%；
PH adjusting agent 4-10%；
Stabilizer 14-30%.
Aforementioned pharmaceutical compositions preferably include following weight percentage components:
Propacetamol Hydrochloride 68-73%；
PH adjusting agent 4-7%；
Stabilizer 20-27%.
Wherein, the pH adjusting agent is selected from citrate-phosphate disodium hydrogen, citric acid-sodium citrate, citric acid-hydrogen-oxygen
Change sodium-hydrochloric acid, Acetic acid-sodium acetate, sodium dihydrogen phosphate-disodium hydrogen phosphate, any one group in dipotassium hydrogen phosphate-sodium hydroxide it is slow
Electuary, preferably citrate-phosphate disodium hydrogen buffer.
Wherein, the stabilizer is in glycine, mannitol, sorbierite, glycerol, glucose, trehalose and sucrose
Any one or a few mixture, preferably glycine.
The pharmaceutical composition more preferably includes following weight percentage components:
Propacetamol Hydrochloride 68-73%；
Citrate-phosphate disodium hydrogen buffer 4-7%；
Glycine 20-27%；
The sum of said components weight percent is 100%；Wherein, citric acid accounts for the weight percentage of pharmaceutical composition and is
2.2-2.9%, the weight percentage that disodium hydrogen phosphate accounts for pharmaceutical composition is 1.8-4.2%.
Most preferred mode is that the pharmaceutical composition includes following weight percentage components:
Propacetamol Hydrochloride 70%；
Citrate-phosphate disodium hydrogen buffer 6%；
Glycine 24%；
Wherein, it is 2.8% that citric acid, which accounts for the weight percentage of pharmaceutical composition, and disodium hydrogen phosphate accounts for pharmaceutical composition
Weight percentage is 3.2%.
Wherein, the dosage form of the pharmaceutical composition is preferably freeze drying powder injection.Wherein, the freeze drying powder injection is dissolved in
In water for injection, the pH value range of aqueous solution is 4.0-8.0, preferably 4.0-5.0.
The preparation method of the pharmaceutical composition of the above-mentioned hydrochloric Propacetamol of injection, includes the following steps:
(1) Propacetamol Hydrochloride and stabilizer of formula ratio are added in water for injection, aseptically stirring makes it
Dissolution；
(2) pH adjusting agent of formula ratio is added in the system obtained to step (1), through 0.22 μm of -0.45 μm of sterile micropore
Membrane filtration 2-3 times filtrate；
(3) filtrate that step filtrate (2) obtains is freeze-dried to obtain the final product.
Wherein, the freeze drying process route are as follows:
Filtrate is placed in pre-freeze in freeze drying box by a. pre-freeze, and temperature is -40 ± 5 DEG C, and the time is 1-5 hours；
B. distil, after drug freezes, open condenser, when condenser temperature reaches -50 DEG C, open vacuum system, make be
Vacuum degree of uniting reaches 10Pa, maintains 1 hour；Start heating device, so that drug temperature is maintained at -20 ± 5 DEG C, the time is that 6-10 is small
When；
C. heat up drying, drug is warming up to 40-45 DEG C, vacuum heat-preserving is 6-8 hours dry.
The freeze drying process route is preferred are as follows: filtrate is placed in pre-freeze in freeze drying box by a. pre-freeze, and temperature is -40
± 5 DEG C, the time is 4 hours；
B. distil, after drug freezes, open condenser, when condenser temperature reaches -50 DEG C, open vacuum system, make be
Vacuum degree of uniting reaches 10Pa, maintains 1 hour；Start heating device, so that drug temperature is maintained at -20 ± 5 DEG C, the time is 8 hours；
C. heat up drying, drug is warming up to 40-45 DEG C, vacuum heat-preserving is 8 hours dry.
The utility model has the advantages that pharmaceutical composition of the invention be freeze drying powder injection, can be avoided as much as moisture, oxygen, pH,
Influence of the factors such as temperature, illumination to Propacetamol Hydrochloride, improves its stability, effectively reduces the generation in relation to substance, thus
Reduce risk when injection.
The pharmaceutical composition of the hydrochloric Propacetamol of injection of the invention, can effectively prevent Propacetamol Hydrochloride to hydrolyze,
Keep Propacetamol Hydrochloride appearance, character, content more stable, slowly, reduces phlebitis with pH value of solution variation when injection compatibility
Incidence, when clinical application, are safer.
Specific embodiment
According to following embodiments, the present invention may be better understood.However, as it will be easily appreciated by one skilled in the art that real
It applies content described in example and is merely to illustrate the present invention, without sheet described in detail in claims should will not be limited
Invention.
Embodiment 1
The eight groups of Propacetamol Hydrochloride pharmaceutical compositions obtained according to the present invention, contain: Propacetamol Hydrochloride, pH are adjusted
Agent, stabilizer, these composition features are as shown in table 1.According to the amounts of components in table 1, by A-H group main ingredient Propacetamol Hydrochloride
Be dissolved separately in 1000ml water for injection with stabilizer, then be separately added into the pH adjusting agent of each group formula ratio, with 0.22 μm-
Sterile filtering with microporous membrane 2-3 times of 0.45 μm.Every group of liquid subpackage is put into pre-freeze in freeze drying box in 1000 vials,
Temperature is -40 ± 5 DEG C, and the time is 4 hours；After drug freezes, condenser is opened, when condenser temperature reaches -50 DEG C, is opened true
Empty set system makes system vacuum up to 10Pa, maintains 1 hour；Start heating device, drug temperature is made to be maintained at -20 ± 5 DEG C, when
Between be 8 hours；Drug is warming up to 40-45 DEG C again, vacuum heat-preserving is 8 hours dry.According to Propacetamol Hydrochloride lyophilized technique system
Sample obtained by standby, hydrochloric Propacetamol 1g or 2g in every drug.
1 eight groups of Propacetamol Hydrochloride pharmaceutical compositions of table
Embodiment 2
Study on the stability under different condition is carried out to eight groups of pharmaceutical compositions in embodiment 1.Take eight groups of pharmaceutical compositions
Lyophilized preparation, placed 10 days under the conditions of 60 DEG C of high temperature or illumination 45001x, measure the 0th day, 5 days, 10 days pharmaceutical compositions
Appearance, solution colour, pH value, content's index.In test sample when solution colour, pH value, content's index, with appropriate injection
One bottle (Propacetamol Hydrochloride content 1,2g) in water 50 or 100ml dissolution embodiment 1, preparing, which becomes Propacetamol Hydrochloride, injects
Liquid 20mg/ml.See Table 2 for details for the testing result of eight groups of Propacetamol Hydrochloride compositions in embodiment 1.In eight groups of Propacetamol Hydrochlorides
In lyophilized preparation, A-E group pharmaceutical composition is more stable, places 10 days at different conditions, and solution colour, contains quantitative change at pH value
Change is smaller, and the apparent condition of A, C group is best, still keeps white loose shape after placing 10 days；F-H group Propacetamol Hydrochloride freeze-drying system
Agent is unstable, and F group changes of contents is larger, G, H group solution changes color and unclarity.
The stability of 2 eight groups of pharmaceutical compositions of table at different conditions
Embodiment 3
Stability is carried out in 0.9% sodium chloride injection to five groups of pharmaceutical compositions of A-E more stable in embodiment 2 to examine
It examines.Propacetamol Hydrochloride lyophilized preparation in embodiment 2 is dissolved in 0.9% sodium chloride injection, the third pa of hydrochloric acid being configured to
Injection can direct clinical administration for he.By A-E group pharmaceutical composition of the present invention, commercially available hydrochloride for injection Propacetamol, (nothing is appointed
The addition of what auxiliary material) with 0.9% sodium chloride injection compatibility, survey its compatibility 0,15,30, pH value and content value after sixty minutes.Such as
Shown in table 3, after A-E group pharmaceutical composition of the invention and 0.9% sodium chloride injection compatibility, pH value of solution, which reduces speed, to be slowed down,
After compatibility 15 minutes, pH value of solution is 4.0 or so, and changes of contents is small；And commercially available Propacetamol Hydrochloride compatibility is after 15 minutes,
PH value of solution < 4, changes of contents are larger.Wherein A, C, E group pH variation and changes of contents are smaller；C, E group solution is after 1h, molten
Liquid pH is still greater than 4, reduces phlebitis risk；The variation of C group solution content is smaller, more steady with 0.9% sodium chloride injection compatibility
It is fixed.Therefore Propacetamol Hydrochloride composition of the invention can effectively reduce Propacetamol Hydrochloride hydrolysis and cause the biggish change of pH value of solution
Change, thereby reduces the bring phlebitis risk of injection pH < 4；The changes of contents for reducing Propacetamol Hydrochloride simultaneously, makes hydrochloric acid
Propacetamol and 0.9% sodium chloride injection compatibility are more stable.
3 pharmaceutical composition A-E group of table is compared with marketed drugs are in the stability in 0.9% sodium chloride injection
In conclusion hydrochloride for injection Propacetamol composition stability prepared by the present invention is good, highly-safe, can prevent
Only Propacetamol hydrolysis causes the variation of pH, content, can reduce the phlebitis risk occurred when clinical application, can enhance clinic and match
Stability when 5.
Claims (10)
1. a kind of pharmaceutical composition of the hydrochloric Propacetamol of injection, which is characterized in that the group including following weight percent
Point:
Propacetamol Hydrochloride 66-75%；
PH adjusting agent 4-10%；
Stabilizer 14-30%.
2. pharmaceutical composition according to claim 1, which is characterized in that including following weight percentage components:
Propacetamol Hydrochloride 68-73%；
PH adjusting agent 4-7%；
Stabilizer 20-27%.
3. pharmaceutical composition according to claim 1 or 2, which is characterized in that the pH adjusting agent is selected from citric acid-phosphorus
Sour disodium hydrogen, citric acid-sodium citrate, citric acid-sodium hydroxide-hydrochloric acid, Acetic acid-sodium acetate, sodium dihydrogen phosphate-phosphoric acid hydrogen two
Any one group of buffer in sodium, dipotassium hydrogen phosphate-sodium hydroxide.
4. pharmaceutical composition according to claim 3, which is characterized in that the pH adjusting agent is citrate-phosphate hydrogen
Disodium buffer.
5. pharmaceutical composition according to claim 1 or 2, which is characterized in that the stabilizer is selected from glycine, sweet dew
Any one or a few mixture in alcohol, sorbierite, glycerol, glucose, trehalose and sucrose.
6. pharmaceutical composition according to claim 5, which is characterized in that the stabilizer is glycine.
7. according to pharmaceutical composition described in claim 2,4 or 6, which is characterized in that the pharmaceutical composition includes as follows
The component of weight percent:
Propacetamol Hydrochloride 68-73%；
Citrate-phosphate disodium hydrogen buffer 4-7%；
Glycine 20-27%；
The sum of said components weight percent is 100%；Wherein, it is 2.2- that citric acid, which accounts for the weight percentage of pharmaceutical composition,
2.9%, the weight percentage that disodium hydrogen phosphate accounts for pharmaceutical composition is 1.8-4.2%.
8. pharmaceutical composition according to claim 1 or 2, which is characterized in that the dosage form of the pharmaceutical composition is to freeze
Dry powder injection.
9. pharmaceutical composition according to claim 8, which is characterized in that the freeze drying powder injection is dissolved in water for injection
In, the pH value range of aqueous solution is 4.0-8.0.
10. the preparation method of the pharmaceutical composition of the hydrochloric Propacetamol of injection described in claim 1, which is characterized in that
Include the following steps:
(1) Propacetamol Hydrochloride and stabilizer of formula ratio are added in water for injection, aseptically stirs to dissolve；
(2) pH adjusting agent of formula ratio is added in the system obtained to step (1), through 0.22 μm of -0.45 μm of sterile miillpore filter
Filter 2-3 times to obtain filtrate；
(3) filtrate that step filtrate (2) obtains is freeze-dried to obtain the final product；
Wherein, the freeze drying process route are as follows:
Filtrate is placed in pre-freeze in freeze drying box by a. pre-freeze, and temperature is -40 ± 5 DEG C, and the time is 1-5 hours；
B. it distils, after drug freezes, opens condenser, when condenser temperature reaches -50 DEG C, open vacuum system, keep system true
Reciprocal of duty cycle reaches 10Pa, maintains 1 hour；Start heating device, so that drug temperature is maintained at -20 ± 5 DEG C, the time is 6-10 hours；
C. heat up drying, drug is warming up to 40-45 DEG C, vacuum heat-preserving is 6-8 hours dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554169.5A CN109200023A (en) | 2017-07-07 | 2017-07-07 | A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710554169.5A CN109200023A (en) | 2017-07-07 | 2017-07-07 | A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109200023A true CN109200023A (en) | 2019-01-15 |
Family
ID=64991309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710554169.5A Pending CN109200023A (en) | 2017-07-07 | 2017-07-07 | A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109200023A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269138A (en) * | 2020-02-27 | 2020-06-12 | 海南全星制药有限公司 | Method for efficiently preparing propacetamol hydrochloride for injection |
| CN111821278A (en) * | 2020-06-19 | 2020-10-27 | 山西振东泰盛制药有限公司 | Propacetamol hydrochloride microcapsule for injection and preparation method thereof |
| CN115501192A (en) * | 2022-10-21 | 2022-12-23 | 海南皇隆制药股份有限公司 | Preparation method of propacetamol hydrochloride for injection |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101147735A (en) * | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | Pharmaceutical composition for injection and its medicine box |
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
-
2017
- 2017-07-07 CN CN201710554169.5A patent/CN109200023A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101330905A (en) * | 2005-11-18 | 2008-12-24 | 赛多斯有限责任公司 | Lyophilization process and products obtained thereby |
| CN101147735A (en) * | 2006-09-19 | 2008-03-26 | 沈阳华泰药物研究有限公司 | Pharmaceutical composition for injection and its medicine box |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111269138A (en) * | 2020-02-27 | 2020-06-12 | 海南全星制药有限公司 | Method for efficiently preparing propacetamol hydrochloride for injection |
| CN111269138B (en) * | 2020-02-27 | 2023-05-05 | 海南全星制药有限公司 | Method for efficiently preparing propacetamol hydrochloride for injection |
| CN111821278A (en) * | 2020-06-19 | 2020-10-27 | 山西振东泰盛制药有限公司 | Propacetamol hydrochloride microcapsule for injection and preparation method thereof |
| CN115501192A (en) * | 2022-10-21 | 2022-12-23 | 海南皇隆制药股份有限公司 | Preparation method of propacetamol hydrochloride for injection |
| CN115501192B (en) * | 2022-10-21 | 2024-02-23 | 海南皇隆制药股份有限公司 | Preparation method of propacetamol hydrochloride for injection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105434373B (en) | A kind of injection Oxiracetam lyophilized preparation and preparation method thereof | |
| CN101330912A (en) | Pharmaceutical composition of docetaxel, preparation method and purpose | |
| HRP20130772T1 (en) | Compositions comprising supramolecular insulin assemblies useful for the treatment of diabetes | |
| CN109200023A (en) | A kind of pharmaceutical composition of the hydrochloric Propacetamol of injection | |
| BR112020019192A2 (en) | PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS DEOXICOLIC ACID | |
| KR20090095668A (en) | A forsythoside injection and preparation thereof | |
| RU2532354C1 (en) | INJECTABLE FORM OF 5α ANDROSTANE-3β,5,6β-TRIOL AND METHOD FOR PREPARING IT | |
| MXPA04010579A (en) | An injection made from ixeris sonchifolia. | |
| CN103877032B (en) | Vecuronium bromide pharmaceutical composition for injection and preparation method thereof | |
| CN103845295A (en) | Palonosetron preparation for injection and preparation method thereof | |
| CN102949353B (en) | oxaliplatin lyophilized pharmaceutical composition for injection and | |
| CN111346061A (en) | Chlorogenic acid composition and preparation method thereof | |
| CN101337070B (en) | Freeze-dried attenuated live vaccine for hepatitis A and its preparing process | |
| CN103637985B (en) | A kind of stable PGE1 lyophilizing breast and preparation method thereof | |
| CN101703466A (en) | Borneol injection and preparation method thereof | |
| CN106729639B (en) | A kind of insulin glargine injecta and preparation method thereof | |
| CN103304424A (en) | Diisopropylamine dichloroacetate compound and compound medicine composition injection thereof | |
| CN103585119A (en) | Stabilization preparation containing epoprostenol and medical salt of epoprostenol and preparation method of stabilization preparation | |
| CN106176626B (en) | L-alanine- (14-oridonin) ester parenteral pharmaceutical composition | |
| CN107982220A (en) | A kind of aspirin-Al-lysine for injection composition of anti-hydrolysis and preparation method thereof | |
| NO781688L (en) | PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICAL ACTIVE AGENTS | |
| CN107823130A (en) | A kind of preparation method of tetrandrine injection agent medicine composition | |
| RU2332994C1 (en) | Method for obtaining stable calcium gluconat solution for injections | |
| CN103877578B (en) | Pharmaceutical naloxone hydrochloride composition for injection and preparation method of pharmaceutical naloxone hydrochloride composition | |
| CN105999278A (en) | Injecting medicine composition for improving stability of ginsenoside medicine injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190115 |